Obesity Drug One-Year Data Sufficient For Safety and Efficacy – Cmte
This article was originally published in The Pink Sheet Daily
Executive Summary
Weight-loss drug trials should include one-year of data on at least 1,500 patients, FDA’s Endocrinologic & Metabolic Drugs Advisory Committee says. Run-in periods prior to clinical trials are unnecessary, committee members agree.
You may also be interested in...
Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies
The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.
Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies
The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.
FDA Obesity Drug Guidance Should Relax Trial Enrollment Criteria, PhRMA Says
Patients with a body mass index exceeding 25, rather than BMI>27, should be allowed in trials, PhRMA says. Revised guidance should also eliminate the need for a weight-loss attempt immediately before enrollment, the association suggests.